[HTML][HTML] Osteoarthritis phenotypes and novel therapeutic targets
WE Van Spil, O Kubassova, M Boesen… - Biochemical …, 2019 - Elsevier
The success of disease-modifying osteoarthritis drug (DMOAD) development is still elusive.
While there have been successes in preclinical and early clinical studies, phase 3 clinical …
While there have been successes in preclinical and early clinical studies, phase 3 clinical …
[PDF][PDF] Osteoarthritis phenotypes and novel therapeutic targets
WE Van Spil, O Kubassova, M Boesen… - Biochemical …, 2019 - core.ac.uk
The success of disease-modifying osteoarthritis drug (DMOAD) development is still elusive.
While there have been successes in preclinical and early clinical studies, phase 3 clinical …
While there have been successes in preclinical and early clinical studies, phase 3 clinical …
Osteoarthritis phenotypes and novel therapeutic targets
WE Van Spil, O Kubassova, M Boesen… - Biochemical …, 2019 - research.regionh.dk
The success of disease-modifying osteoarthritis drug (DMOAD) development is still elusive.
While there have been successes in preclinical and early clinical studies, phase 3 clinical …
While there have been successes in preclinical and early clinical studies, phase 3 clinical …
[PDF][PDF] Osteoarthritis phenotypes and novel therapeutic targets
WE Van Spil, O Kubassova, M Boesen… - Biochemical …, 2019 - scholar.archive.org
The success of disease-modifying osteoarthritis drug (DMOAD) development is still elusive.
While there have been successes in preclinical and early clinical studies, phase 3 clinical …
While there have been successes in preclinical and early clinical studies, phase 3 clinical …
Osteoarthritis phenotypes and novel therapeutic targets.
WE Van Spil, O Kubassova, M Boesen… - Biochemical …, 2019 - europepmc.org
The success of disease-modifying osteoarthritis drug (DMOAD) development is still elusive.
While there have been successes in preclinical and early clinical studies, phase 3 clinical …
While there have been successes in preclinical and early clinical studies, phase 3 clinical …
Osteoarthritis phenotypes and novel therapeutic targets
WE Van Spil, O Kubassova… - Biochemical …, 2019 - pubmed.ncbi.nlm.nih.gov
The success of disease-modifying osteoarthritis drug (DMOAD) development is still elusive.
While there have been successes in preclinical and early clinical studies, phase 3 clinical …
While there have been successes in preclinical and early clinical studies, phase 3 clinical …